2022年6月，阿斯利康与青岛市政府签署合作备忘录，计划在青岛投资建设布地格福吸入气雾剂生产供 应基地。据FierrcePharm消息，本次追加投资后，阿斯利康青岛基地总投资额已达8.86亿美元。 文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担, 关于对文中陈述、观点判断保持中 立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自 行承担全部。 来源：市场资讯 （来源：求实药社） 阿斯利康中国官网11月5日信息称，阿斯利康在第8届中国国际进口博览会上宣布追加1.36亿美元投资扩 大青岛生产供应基地产能，进一步提升吸入气雾剂产能。 | Zeneca 2 | 阿斯利康中国网站 6 阿斯利康金利 | | --- | --- | | 〔 关于我们 · 疾病领域 · 科学创新 · 企业责任 · 职业发展 媒体中心 | | | 阿斯利康亮相第八届进博会 深化中国承诺 | | | 加码制造、新药首展、推动可持续发展 | | | 发布日期 2025年 11月 05日 | | ...

Core Viewpoint - AstraZeneca's Breztri inhalation aerosol has been submitted for a new indication in China, likely for asthma treatment, following positive results from two Phase III trials [1][3]. Group 1: Product Information - Breztri inhalation aerosol is a fixed-dose combination therapy that includes budesonide (an inhaled corticosteroid), glycopyrrolate (a long-acting muscarinic antagonist), and formoterol (a long-acting beta-2 adrenergic agonist) [2]. - The product is classified as a chemical drug and is imported, with the application date recorded as September 17, 2025 [2]. Group 2: Clinical Trial Results - Two Phase III studies (KALOS and LOGOS) involving 4,461 poorly controlled asthma patients demonstrated that Breztri significantly improved forced expiratory volume in one second (FEV1) compared to the Symbicort group [3]. - The studies also indicated a significant reduction in the rate of severe asthma exacerbations for patients using Breztri [3]. Group 3: Market Context - Asthma affects up to 262 million people globally, with nearly half of those on dual therapy still experiencing poor control, which limits lung function and quality of life [3].